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Aim The effect of long-term high-intensity statin therapy on coronary atherosclerosis among patients with acute ST-segment
elevation myocardial infarction (STEMI) is unknown. The aim of this study was to quantify the impact of high-intensity
statin therapy on plaque burden, composition, and phenotype in non-infarct-related arteries of STEMI patients undergo-
ing primary percutaneous coronary intervention (PCI).
Methods
and results
Between September 2009 and January 2011, 103 STEMI patients underwent intravascular ultrasonography (IVUS)
and radiofrequency ultrasonography (RF-IVUS) of the two non-infarct-related epicardial coronary arteries (non-
IRA) after successful primary PCI. Patients were treated with high-intensity rosuvastatin (40 mg/day) throughout
13 months and serial intracoronary imaging with the analysis of matched segments was available for 82 patients
with 146 non-IRA. The primary IVUS end-point was the change in per cent atheroma volume (PAV). After 13
months, low-density lipoprotein cholesterol (LDL-C) had decreased from a median of 3.29 to 1.89 mmol/L
(P, 0.001), and high-density lipoprotein cholesterol (HDL-C) levels had increased from 1.10 to 1.20 mmol/L
(P, 0.001). PAV of the non-IRA decreased by20.9% (95% CI:21.56 to20.25, P ¼ 0.007). Patients with regression
in at least one non-IRA were more common (74%) than those without (26%). Per cent necrotic core remained un-
changed (20.05%, 95% CI: 21.05 to 0.96%, P ¼ 0.93) as did the number of RF-IVUS defined thin cap fibroatheromas
(124 vs. 116, P ¼ 0.15).
Conclusion High-intensity rosuvastatin therapy over 13 months is associated with regression of coronary atherosclerosis in non-
infarct-related arteries without changes in RF-IVUS defined necrotic core or plaque phenotype among STEMI patients.
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Introduction
Coronary atherosclerosis is a chronic inflammatory disease, which
may goundetected for decades before it gives rise todiseasemanifes-
tations such as stable, obstructive coronary artery disease, or acute
coronary syndromes (ACS).1 Statin therapy effectively reduces car-
diovascular events in the setting of primary and secondary preven-
tion, with a particular benefit occurring early after treatment
initiation in ACS patients.2 High-intensity rosuvastatin therapy has
been shown to more effectively lower LDL-C and increase HDL-C
compared with other statins.3 Insights from intracoronary imaging
studies suggest that statins result in atheroma regression in patients
with stable, non-obstructive coronary artery disease.4,5 Patients
with STEMI are at high risk for recurrent atherothrombotic events,
which is related tomultifocal diseasewith a highprevalenceof vulner-
able plaques,6,7 typically extending beyond the culprit site due to
widespread inflammation in other plaques including increased prote-
ase activity.8 The primary hypothesis of the present study was that
coronary atherosclerosis regression can be achieved in the presence
of the high-intensity rosuvastatin therapy (40 mg daily) in the prox-
imal segments of non-infarct-related arteries (IRA)within 13months.
Due to the importance of plaque phenotype for future cardiovas-
cularevents, there is an interest in the studyof changes inplaquecom-
position in response to high-intensity statin therapy. The use of
radiofrequency intravascular ultrasonography (RF-IVUS) has been
validated for the detection of a necrotic core9 and plaque character-
ization10 based on ex vivo histological analyses, providing the means
for serial in vivo assessment of plaque composition and phenotype.
Therefore, the secondary hypothesis of this study was that high-
intensity rosuvastatin therapy results in a reduction of RF-IVUS
defined necrotic core and a decrease in the frequency RF-IVUS
defined thin cap fibroatheromas (TCFA).
Methods
Study design
Integrated biomarker imaging study (IBIS 4) (NCT00962416) is a pro-
spective cohort study nested into the COMFORTABLE-AMI, a trial
which compared the safety and efficacy of biolimus-eluting stents with
bare metal stents in 1161 STEMI patients undergoing primary PCI at 11
international centres.11,12 A total of 103 patients were enrolled in this
intracoronary imaging study at five predefined centres using serial IVUS
and RF-IVUS investigations to quantify changes in atherosclerotic
plaque characteristics in non-IRA under long-term high-intensity statin
therapy. Patients enrolled in the clinical trial were screened for clinical
and anatomic feasibility to undergo the serial intracoronary imaging
protocol. All the patients provided written informed consent, and the
study was approved by the institutional review boards of all participating
centres.
Patient population
Patients were considered for enrolment if they were included in the
COMFORABLE-AMI trial and fulfilled the following additional criteria:
age ,90 years, preserved renal, and liver function, haemodynamic sta-
bility allowing the repetitive administration of nitroglycerine, TIMI flow
≥2of the IRAat the completionof primary PCI, and a coronary anatomy
suitable for intracoronary imaging in two major proximal coronary ar-
teries in the absence of a lesion qualifying for treatment (stenosis
.50%). Intracoronary imaging was directed at the non-treated prox-
imal part (50 mm) of non-IRA. The inclusion was independent of the
lipid status and intake of pre-existing lipid-lowering therapy. All the
patients received treatment with rosuvastatin at an initial dose of
20 mg once daily during the first 2 weeks to assess compliance and
adverse effects followed by 40 mg once daily for the remainder of the
follow-up period.
Procedures
Intravascular ultrasonography at baseline
Following successful primary PCI (i.e. TIMI flow ≥2), the infarct-related
vessel was imaged first (data not reported here), followed by intracoron-
ary imaging of the proximal 50 mm of the two non-IRA. The region
of interest (ROI) was selected between two anatomical landmarks
(distal: sidebranch, proximal: LM bifurcation or ostium of the RCA).
A 20-MHz ultrasound catheter (Eagle Eye, Volcano Cooperation,
Rancho Cordova, CA) was advanced beyond the distal landmark and a
motorized pullback at a speed of 0.5 mm/s was performed after the
administration of 200 mg intracoronary nitroglycerine. Images were
acquired with 30 frames per second and recorded on a DVD. Record-
ings were sent to an independent Core Laboratory (Cardialysis B.V.,
Rotterdam, The Netherlands) for quality control; only if pre-specified
criteria were met, the runs were considered for analysis.
Intravascular ultrasonography at follow-up
All the patients were scheduled for intracoronary imaging follow-up at
13 months. Prior to the imaging, the operator was provided with a
summary information on the distal and proximal landmarks used at base-
line to achieve a maximal overlap of the acquired pullbacks. If a patient
underwent symptom-driven repeat angiography prior to the 13 months
visit, the intracoronary imaging protocol was allowed to be repeated as
early as 10 months after primary PCI but not earlier. In case of an inter-
mittent revascularization of a previously imaged ROI, it was recom-
mended to perform IVUS prior to revascularization at any timepoint if
technically and clinically feasible.
Intravascular ultrasonography analysis
Only after availability of the serial IVUS recordings, an independent
person randomly allocateda code to thebaseline and follow-uppullbacks
in order to ensure blinding of the analysts to the temporal sequence of
paired images. An analyst not involved in the actual analysis evaluated
the quality of the recordings andwas responsible for deleting the proced-
ure date and any other identifying information. The statistician was pro-
vided with the coding list to unblind the temporal sequence and to
perform the data analysis only after the entire imaging analysis had
been completed and the statistical analysis was at an advanced stage.
A technician assessed the largest common ROI available from the two
serial recordingswith thehelpof a dedicatedmatching software and iden-
tified as much common matching points within the pullbacks (e.g. side-
branches, calcifications). Within the matched ROI, the lumen and the
external elastic membrane were measured in every frame (0.4 mm)
using a validated software (QIVUS, Medis, Leiden, The Netherlands).
Intravascular ultrasonography end-points
Serial IVUS data were derived from the matched ROI and for the most
diseased 10 mm segment at baseline. The primary end-point of the
studywas the change inper cent atheromavolume (PAV). The calculation
of all IVUS and RF-IVUS end-points is shown in Supplementary material
online, Appendix.
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The secondary end-point of the studywas the change in RF-IVUS defined
per cent volume necrotic core. The plaque composition analysis using
IVUSwasobtained by processing theRF signals in a dedicated offline soft-
ware (QIVUS, Medis, Leiden, The Netherlands). In this software Volca-
no’s proprietary virtual histology (VHw) IVUS analysis technology is
integrated. This results in the characterization of four different tissue
types: necrotic core (red), dense calcium (white), fibro-fatty (light
green), and fibrous (green). In addition, a lesion type analysis was per-
formed according to the PROSPECT study methodology.13,14 The
detailed lesion assessment is explained in Supplementary material
online, Appendix.
Statistical analysis
Baseline and medication characteristics were analysed with Pearson x2,
Wilcoxon rank-sum, Fisher’s exact, and t-tests as appropriate. Lipid
values were reported as median and inter-quartile range (IQR).
Change in lipid values was analysed with paired patient-level data with
Wilcoxon signed-rank tests. Absolute changes were reported and
tested except, if necessary to fulfil symmetry assumption, analysis was
done on the log-transformed values and relative changes were reported
and tested. In most patients, IVUS datawere available for two non-IRA at
baseline and 13-month follow-up. The absolute change from baseline to
follow-upwas derived at vessel level as end-point (FUP)minus end-point
(BL) such that a negative value indicates a decrease over time. The
changes were analysed with linear mixed models with patient as
random intercept to account for the non-independence of end-points
from the same patient. Two-sided P-values quantify the statistical evi-
dence that the absolute change is different from zero. The results of
the stratified analysis in Figure 3 is based on the same method but an
additional interaction P-value is provided to quantify the evidence that
change was different between the strata. To assess the association
between changes in LDL-C and HDL-C and change in PAV (Figure 4),
we stratified the patients into four groups with a quartile split on the
Figure 1 Flow chart of integrated biomarker imaging study 4 imaging study; *1 patient had 3 major non-infarcted epicardial coronary vessels
(e.g. intermediate branch) who underwent serial intracoronary imaging.
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change in cholesterol values. The associationwas assessedbyestimating
the linear trend from a regression model for PAV change against the
four ordered groups. Change in proportion of the TCFA lesion type
was analysed with binomial generalized estimating equations to
account for correlation of lesions within patient. Statistical analyses
were performed with Stata (StataCorp, College Station, TX, USA)
and the computing environment R (The R Foundation for Statistical
Computing) with package nlme and geepack. All reported confidence
intervals have 95% coverage.
Results
Patient characteristics
Between September 2009 and January 2011, 103 (out of 602 STEMI
patients enrolled into theCOMORTABLEAMI trial at all intracoron-
ary imaging sites) underwent primary PCI and IVUS and RF-IVUS of
both non-IRA. The flow chart in Figure 1 provides detailed informa-
tionon thenumberof patients and vessels included into thefinal ana-
lysis. For the final serial IVUS and RF-IVUS analysis, a total of 82
patients with 146 vessels were available. Baseline clinical character-
istics were similar for patients undergoing serial intracoronary
imaging and those not undergoing serial imaging (Table 1). Patients
enrolled into the intracoronary imaging study—as opposed to
those participating in the clinical trial only—were younger, more
likely male, more obese, and had a lower frequency of hyperlipid-
aemia compared with those participating in the clinical follow-up
protocol (Supplementary material online, Table S1). Cardiovascular
medication and statin therapy is summarized in Table 2. A total of 8
(10%) patients were on statin treatment at the timepoint of study in-
clusion with none of them receiving high-intensity statin therapy.
Lipid profile
The lipid profile at the timepoint of inclusion, 30, and 13 months is
summarized in Figure 2. HDL-C levels increased from 1.10 mmol/L
(IQR: 0.96–1.26) to 1.20 mmol/L (IQR: 1.00–1.48) (P, 0.0001),
and LDL-C decreased from a from 3.29 mmol/L (IQR: 2.78–3.75)
to 1.89 mmol/L (IQR: 1.60–2.32) at 13 months (P, 0.0001).
A total of 44% of patients achieved a guideline-recommended
LDL-C level of ≤1.8 mmol/L at a 13-month follow-up.
Ultrasonography findings
Table 3 summarizes the results of the serial changes in IVUS para-
meters. After 13 months of high-intensity rosuvastatin therapy, the
primary IVUS end-point change in PAV amounted to 20.90% (CI:
21.56 to 20.25%; P ¼ 0.007) with a reduction from 43.95+
9.66% at baseline to 43.02+ 9.82% at follow-up. The reduction
within the worst 10 mm was more pronounced as shown in
Table 3; 74% of patients had at least one vessel with disease regres-
sion, 54% of patients showed regression in both vessels, and 65%
of patients had a mean PAV reduction (i.e. mean PAV change ,0).
In stratified analyses of the primary IVUS end-point change in PAV
(Figure 3), the decrease in PAV was consistent in most subgroups
with the exception of patients with diabetes mellitus, in whom a
less pronounced reduction of PAV was observed compared with
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Table 1 Baseline patient characteristics
Number of patients All imaging patients
(n5 103)
Serial IVUS available
(n5 82)
No serial IVUS available
(n5 21)
P value (serial vs.
no serial)
Age 58.2+10.5 58.5+9.9 57.1+12.9 0.58
Female sex (%) 10 (9.7) 6 (7.3) 4 (19.0) 0.12
BMI 27.8+4.2 27.5+3.8 29.0+5.5 0.17
Cardiovascular risk factors (%)
Diabetes 13 (12.6) 9 (11.0) 4 (19.0) 0.46
Hypertension 48 (46.6) 39 (47.6) 9 (42.9) 0.81
Hypercholesterolaemiaa 42 (40.8) 36 (43.9) 6 (28.6) 0.23
Current smoker 47 (45.6) 35 (42.7) 12 (57.1) 0.33
Family history of CAD 31 (31.0) 25 (31.6) 6 (28.6) 1.00
Renal failureb 5 (5.0) 3 (3.8) 2 (9.5) 0.28
Previous myocardial infarction 2 (1.9) 2 (2.4) 0 (0.0) 1.00
Previous PCls 1 (1.0) 1 (1.2) 0 (0.0) 1.00
Clinical presentation
Time from symptom onset to balloon
inflation (min)
258 (170; 472) 262 (170; 479) 238 (167; 387) 0.67
Left ventricular ejection fraction
(angiography)
47.8+9.4 47.5+8.8 49.4+12.0 0.47
Resuscitation prior to hospital arrival (%) 5 (4.9) 5 (6.1) 0 (0.0) 0.58
Values reported are n (%); mean+ SD; or median (lower quartile; upper quartile).
aTotal cholesterol .5.0 mmol or 190 mg/dL or requiring treatment.
b,60 eGFR.
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patients without diabetes (P for interaction ¼ 0.054).
The association between baseline LDL-C and HDL-C and their
change over 13 months with the change in PAV is shown in
Figure 4. When stratifying patients into quartiles according to
LDL-C reduction or HDL-C increase, a significant linear trend was
observed for the reduction in per cent atheroma. The change in
PAVwas independent of baselineHDL-C and LDL-C levels (Figure 4).
To eliminate concerns of bias introduced by imaging of more than
one vessel per patient, weperformed a sensitivity analysis,which only
used data from one vessel in case there were two, giving preference
to LAD over LCX over RCA. Results remained essentially the same
(PAV reduction 21.07%, CI: 21.86 to 20.28%, P ¼ 0.009) (Supple-
mentary material online, Table S2).
Radiofrequency intravascular
ultrasonography defined tissue
composition
Serial RF-IVUS data are summarized in Table 4. There was no signifi-
cant change in the secondary end-point of RF-IVUS defined per cent
necrotic core between baseline and follow-up (20.05%; CI: 21.05
to 0.96%; P ¼ 0.93), whereas the proportion of calcified tissue com-
ponents increased (+1.28%; CI: 0.66 to 1.90%; P, 0.0001) and
fibrous tissue components decreased (21.38%; CI: 22.28 to
20.47%;P ¼ 0.003).As anexploratoryanalysis,wecalculated the ab-
solute changes in tissuecomposition (Supplementarymaterial online,
Table S3), and noted a small but significant reduction in a necrotic
core [20.08 mm2 (20.13 mm2 to 20.03 mm2, P ¼ 0.002)].
Radiofrequency intravascular
ultrasonography defined lesion phenotype
Serial lesion-relatedRF-IVUS at baseline and 13months are provided
inTable 5. In the entireproximal, non-infarct-relatedvessel segments,
164 atherosclerotic lesions were observed at baseline (2 per patient,
1 per analysed non-IRA), of which RF-IVUS definedTCFAweremost
frequent (n ¼ 124 (75%). At 13-month follow-up, 158 lesions were
observed (7 resolved, 1 new lesion), with 116 (70%) RF-IVUS
defined TCFAs. A total of 17 RF-IVUS defined TCFAs observed at
baseline converted into lower risk lesion types at follow-up and
nine TCFAs were newly formated (7 from a ThCFA lesion and 1
from a PIT lesion), corresponding to a change in proportion of
TCFA from 75% at baseline to 70% at 13 months (P ¼ 0.15).
Discussion
This serial intracoronary imaging study investigated the effects of
high-intensity rosuvastatin therapy on coronary atherosclerosis in
terms of plaque burden, RF-IVUS defined plaque composition and
phenotype in the proximal segments of non-IRA of patients present-
ing with acute STEMI (Figure 5).
In the present study, high-intensity rosuvastatin therapy over 13
months reduced mean plasma LDL-C achieving a treatment target
of ,1.8 mmol/L in 44% of patients. Serial intracoronary imaging
revealed that high-intensity lipid-lowering therapy resulted in regres-
sion of coronary atherosclerosis in the proximal segments of
non-IRA among STEMI patients. Two previous studies have reported
regression of coronary atherosclerosis among lower risk patients
with stable, non-obstructive coronary artery disease under high-
intensity rosuvastatin therapy.4,5 The results of the present study
investigating high-risk STEMI patients using multi-vessel intracoron-
ary imaging and analysis by a different Core Laboratory yielded
similar results as those observed in the Effect of very high-intensity
statin therapy on regression of coronary atherosclerosis (ASTEROID)
trial. In this trial, the reduction in PAV amounted to 20.98+
3;15% and total atheroma volume was reduced by 214.7+
25.7 mm3; despite a longer duration of therapy (13 vs. 24 months)
and lower on target lipid levels. Of note, atheroma burden in the
present study was in average higher (10%) reflecting the higher
risk population. Despite the exclusion of patients with obstructive
coronary artery disease of non-IRA, this observation underscores
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Table 2 Cardiovascular medications
Number of
patients
Serial IVUS
available
(n 5 82)
NO serial
IVUS available
(n 5 21)
P-value
Statin use prior to
enrolmenta (%)
8 (9.8) 3 (14.3) 0.69
At 30 days (%)
Aspirin 82 (100.0) 19 (95.0) 0.20
Prasugrel 64 (78.0) 15 (75.0) 0.77
Clopidogrel 18 (22.0) 4 (20.0) 1.00
Any DAPT 82 (100.0) 18 (90.0) 0.04
Beta-blocker 78 (95.1) 18 (90.0) 0.34
ACE inhibitor 60 (73.2) 13 (65.0) 0.58
Statin 82 (100.0) 20 (100.0)
Rosuvastatin (%)
10 mg 1 (1.2) 2 (9.5) 0.09
20 mg 9 (11.0) 1 (4.8) 0.68
40 mg 69 (84.1) 15 (71.4) 0.70
Atorvastatin (%)
40 mg 1 (1.2) 2 (9.5) 0.40
80 mg 2 (2.4) 0 (0.0) 0.40
At 1 year (%)
Aspirin 80 (100.0) 17 (94.4) 0.18
Prasugrel 63 (78.8) 12 (66.7) 0.36
Clopidogrel 14 (17.5) 4 (22.2) 0.74
Any DAPT 76 (95.0) 16 (88.9) 0.30
Beta-blocker 67 (83.8) 15 (83.3) 1.00
ACE inhibitor 45 (56.3) 10 (55.6) 1.00
Statin 81 (98.8) 18 (100.0) 1.00
Rosuvastatin (%)
10 mg 2 (2.4) 3 (14.3) 0.03
20 mg 16 (19.5) 5 (23.8) 0.30
40 mg 59 (72.0) 6 (28.6) 0.02
Atorvastatin (%)
40 mg 1 (1.2) 2 (9.5) 0.40
80 mg 2 (2.4) 0 (0.0) 0.40
Values reported as number of patients (%).
aOther cardiovascular medication regularly taken at home was not recorded.
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the high atherosclerotic disease burden observed in the proximal
segments of non-IRA among STEMI patients.
Although subgroup analyseswere not pre-specified, therewas no
statistical heterogeneity concerning the change in PAV acrossmajor
subgroups (Figure 3). It is of interest that the more pronounced
changes in LDL-C reduction and HDL-C increase over 13 months
resulted in larger changes of PAV reduction (Figure 4), which was
not the case for baseline LDL-C and HDL-C (Figure 4). This obser-
vation as well as the results of a largemeta-analysis of statin therapy,
which reported a significant reduction in vascular events
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Table 3 Serial intravascular ultrasonography results
Number of patients (vessels): 82 (146) Baseline mean+ SD Follow-up mean+ SD Absolute change mean
change (95% CI)
P-value
Entire regions
Region length (mm) 36.15+16.1 36.21+16.05 0.06 (21.06 to 1.17) 0.917
Average lumen area (mm2) 8.64+3.07 8.48+2.89 20.16 (20.29 to 20.03) 0.020
Average vessel area (mm2) 15.74+5.64 15.23+5.38 20.51 (20.67 to 20.35) ,0.001
Primary efficacy parameter
Per cent atheroma volume (%) 43.95+9.66 43.02+9.82 20.9 (21.56 to 20.25) 0.007
Secondary efficacy parameters
Total atheroma volume (mm3) 258.31+163.41 245.13+152.95 213.14 (222.45 to 23.84) 0.006
Average atheroma area (mm2) 7.1+3.22 6.75+3.15 20.35 (20.48 to 20.21) ,0.001
Normalized TAV (mm3) 248.4+112.69 235.95+110.25 212.18 (216.91 to 27.44) ,0.001
Most diseased 10 mm segments
Region length (mm) 9.96+0.15 10.25+2.23 0.29 (20.08 to 0.66) 0.118
Average lumen area (mm2) 7.59+2.97 7.78+2.96 0.22 (20.01 to 0.45) 0.061
Average vessel area (mm2) 16.26+5.61 15.67+5.52 20.57 (20.84 to 20.31) ,0.001
Primary efficacy parameter
Per cent Atheroma volume (%) 52.31+12.17 49.42+11.65 22.94 (23.89 to 21.98) ,0.001
Secondary efficacy parameters
Total atheroma volume (mm3) 86.51+37.94 81.01+38.96 25.5 (28.99 to 22) 0.002
Average atheroma area (mm2) 8.68+3.79 7.9+3.52 20.78 (20.99 to 20.56) ,0.001
Normalized TAV (mm3) 86.44+37.76 78.72+35.08 27.73 (29.86 to 25.59) ,0.001
For descriptive purposes the mean+ SD over all vessels is reported for baseline and follow-up.
Two-sided P-values to test if change is different from 0 are from linear mixed models (patient as random intercept).
TAV, total atheroma volume; PAV, per cent atheroma volume.
Figure 2 Box plots showing median and inter-quartile range for plasma LDL-C, HDL-C, and LDL-C/HDL-C ratio at baseline, 30 days, and
13 months. (A) HDL-C, (B) LDL-C, and (C) the LDL-C/HDL-C ratio. The median per-patient changes and corresponding P-values from the
paired analysis are indicated in the figure.
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independent from the baseline LDL-C levels,15 reinforce the benefit
of high-intensity statin therapy in STEMI patients independent of the
baseline lipid levels.
Radiofrequency intravascular
ultrasonography defined changes
in plaque composition
In two large-scale clinical outcome trials, the use of high-intensity
statin therapywas associatedwith a significant decrease in cardiovas-
cular events compared with the standard statin therapy.2,16 The
improvedclinical outcomehasnotbeendirectlyattributed toathero-
sclerosis regression so far, and it remains unclear whether the bene-
ficial effects of lipid-lowering therapy are related to other effects than
reduction in plaque burden such as changes in plaque composition or
plaque phenotype.17
Despite significant atheroma regression, no change in RF-IVUS
defined per cent necrotic core was observed during serial examina-
tions under high-intensity statin therapy. Two previous studies investi-
gating serial changes inanecrotic corewereperformed inpatientswith
stable, non-obstructive coronary artery disease. The integrated
biomarker imaging study 2 study (IBIS-2)18 using conventional doses
of lipid therapy showed an increase in per cent necrotic core (2.5+
9.6%) throughout 12 months.18 Similarly, the RF substudy of
SATURN,19 which recorded a lower proportion of a necrotic core
at baseline (12.3%) compared with the present STEMI population in
71 patients, observed an increase of 1.9% in a necrotic core (P,
0.001) despite high-intensity statin therapy and a significant reduction
of the atheroma volume. Available evidence therefore suggests that
Figure3 Forrest plot showing the change in PAV (%) stratified according to baseline patient characteristics. Two-sided P-values to test if change is
different from 0 are from linear mixed models (patient as random intercept) and mean change and 95% CI are reported. An interaction P-value is
provided to compare the change between the strata. Hypercholesterolaemia defined as total cholesterol .5.0 mmol or 190 mg/dL or requiring
treatment. *A patient can be both in LAD and non-LAD group and therefore patient numbers sum to .82.
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Figure 4 Forrest plot showing the change in PAV regressed against the baseline values and the changes in LDL-C or HDL-C. Patients were strati-
fied into four groupswith aquartile split according to their LDL-CorHDL-Cbaseline valueorchange.Reportedvalues are theper groupmeans (95%
CI) and the linear trend across the four groups (95%CI) which represents the change in PAV between two consecutive groups. Analysis with linear
mixed model (patient as random intercept).
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Table 4 Serial radiofrequency ultrasonography analysis
Number of patients (vessels):
82 (142a)
Baseline mean+ SD Follow-up mean+ SD Absolute change mean
change (95% CI)
P-value
Entire regions
Per cent volume NC (%) 21.14+7.43 21.02+7.04 20.05 (21.05 to 0.96) 0.926
Per cent volume DC (%) 8.33+5.94 9.56+6.66 1.28 (0.66 to 1.9) ,0.001
Per cent volume FI (%) 59.75+9.33 58.4+9.72 21.38 (22.28 to 20.47) 0.003
Per cent volume FF (%) 10.78+5.19 11.02+5.88 0.21 (20.91 to 1.34) 0.705
Most diseased 10 mm segments
Per cent volume NC (%) 23.11+8.81 22.52+8.8 20.59 (21.82 to 0.63) 0.338
Per cent volume DC (%) 8.77+6.84 10.57+8.03 1.82 (0.89 to 2.74) ,0.001
Per cent volume FI (%) 57.66+11.27 56.45+11.76 21.21 (22.51 to 0.09) 0.068
Per cent volume FF (%) 10.46+6.34 10.46+6.62 20.01 (21.12 to 1.1) 0.991
See footnote of Table 3 for details.
NC, necrotic core tissue; DC, dense calcium tissue; FI, fibrous tissue; FF, fibro-fatty tissue.
a142 of 146 vessels analysed because if total VH area at baseline or follow-up is 0, the % change is not defined.
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high-intensity statin therapydoes not reduce anecrotic core burden as
determined by RF-IVUS during an observation period of 13 months,
which is relatively short compared with otherwise permanent treat-
ment recommendations for secondary prevention.
Statin therapy has been reported to reduce lipid content, oxidized
LDL, and inflammatory cells in tissue extracted bymeans of atherect-
omy.20 In contrast, we did not observe a reduction in RF-IVUS
defined lipid-rich tissue (fibro-fattyor necrotic core) but rather an in-
crease in calcium. An increase in calcium was previously noted inde-
pendent of statin dose using investigation by coronary computed
tomography and RF-IVUS performed at 12 months.18,21,22 Similar
to our findings, the RF-IVUS substudy of SATURN19 observed a sig-
nificant increase in calcium, suggesting that calcium may increase in
the presence of high-intensity statin therapy. In view of the overall
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Table 5 Serial radiofrequency ultrasonographic plaque characterization
13-month follow-up
Baseline 82 patients TCFA ThCFA PIT Fibrotic Fibrocalcific Resolved
Total 165 lesions 116 (70.3%) 24 (14.5%) 8 (4.8%) 6 (3.6%) 4 (2.4%) 7 (4.2%)
TCFA 124 (75.2%) 107 10 1 2 0 4
ThCFA 22 (13.3%) 7 13 0 0 1 1
PIT 10 (6.1%) 1 1 5 1 0 2
Fibrotic 5 (3.0%) 1 0 1 3 0 0
Fibrocalcific 3 (1.8%) 0 0 0 0 3 0
No lesions 1 (0.6%) 0 0 1 0 0 0
Values reported are number of lesions (%).
TCFA, thin cap fibro-atheroma; ThCFA, thick cap fibro-atheroma; PIT, pathological intimal thickening.
Figure 5 Example of a lesion showing a regression (left panel) and progression (right panel). The left cross section (black and white images) indi-
cates the intravascular ultrasonography greyscale findings and the four coloured cross sections on the right indicate radiofrequency intravascular
ultrasonography analysis.
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plaque regression, the increase of calcium may be interpreted as
conversion of non-calcified to calcified plaque rather than a pro-
gression of the underlying atherosclerotic process. Imaging
studies in patients with ACS as well as autopsy studies in sudden
cardiac death patients have suggested less calcification in unstable
plaques when compared with stable plaques,23,24 supporting the hy-
pothesis that calcium may increase plaque stability. The absence of
information on the distribution and localization of the observed cal-
cification process prohibits a full understanding of the observed
change in calcified tissue.
Radiofrequency intravascular
ultrasonography defined changes
in plaque phenotype
Weobserved in average1.5TCFAsas definedbyRF-IVUSperpatient
in the proximal segment of non-IRAs. In a pathology study, TCFAs
defined by histology have been shown to accumulate in the proximal
30 mm segments of the epicardial coronary arteries,25 providing an
explanation for the higher frequency of TCFAs in the present study
compared with the only previous RF-IVUS study investigating
non-IRA lesions.26
Plaque phenotype analysis indicated infrequent changes through-
out the study period, without evidence for transformation into
higher risk plaque phenotypes. Most RF-IVUS defined TCFAs did
not change their characteristics over timewith aminorityof 14%con-
verting into a lower risk phenotype (P ¼ 0.15). In the only available
study using serial intracoronary imaging in STEMI patients26 who
underwent treatment with the standard statin therapy during a
follow-up duration of 13 months, the frequency of TCFAs increased
over time (29%), providing indirect evidence for a hypothetical effect
of high-intensity dose statin therapy, a finding which is hypothesis
generating and warrants further investigation.
Limitations
The results have to be interpreted in the light of the following limita-
tions. Firstly, the analysis was not based on a formal sample size con-
sideration. Rather, it used data from 82 STEMI patients who were
successfully enrolled as part of a substudy of a previously published
randomized trial comparing two stent types in the setting of primary
PCI.12 In an exploratory analysis, the width of the actual 95% confi-
dence interval of thedifference in PAVsuggests that therewas80%
power to detect a difference of 0.94% from baseline to follow-up.
Secondly, the number of patients included into the study of patients
with acute myocardial infarction is considerably smaller compared
with previously reported regression trials in patientswith stable cor-
onary artery disease. Thirdly, this was an observational study
without control group, as we regarded the absence of high-intensity
statin therapy as clinically not acceptable. Another limitation is that
only selected patients underwent serial intracoronary imaging, as
multi-vessel intracoronary imaging in the setting of STEMI is technic-
ally demanding and can only performed in stabilized patients with
patent infarct-vessel. Therefore, these findings may not apply to
unselected STEMI patients with different lesion phenotype. Finally,
repeat imaging was scheduled at 13 months, which might affect the
ability to detect long-term changes in plaque composition and
phenotype.
Conclusion
The proximal segments of non-IRA of STEMI patients feature a high-
atherosclerotic plaque burden and harbour in average 1.5 TCFAs
defined by RF-IVUS per patient. High-intensity rosuvastatin (40 mg/
day) therapy throughout 13months was associated with a significant
reduction of coronary atherosclerosis but no changes in RF-IVUS
defined proportion of necrotic core or other plaque phenotypes.
Regression of coronary atherosclerosis as a result of high-intensity
statin therapy among STEMI patients may have important long-term
clinical implications.
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